Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5442-5449

  Sahota, Tarjinder ^a   Pasqua, Oscar Della ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SIMULATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; ETHNIC GROUPS; FEMALE; HUMANS; ISONIAZID; LIVER; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84868035443     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05988-11     Document Type: Article

References (53)

1. Acocella G, Angel JH. 1986. Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase. Am. Rev. Respir. Dis. 134:1283-1286.
2. Acocella G, et al. 1993. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. Monaldi Arch. Chest Dis. 48: 205-209.
3. Agrawal S, et al. 2004. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int. J. Pharm. 276:41-49.
4. Angel JH, Somner AR, Citron MK. 1979. Toxicity of antituberculosis drugs with special reference to hepatotoxicity. Bull. Int. Union Tuberc. 54:47-48.
5. Baghaei P, et al. 2010. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am. J. Ther. 17:17-22.
6. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
7. Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. 2010. A model-based approach to dose selection in early pediatric development. Clin. Pharmacol. Ther. 87:294-302.
8. Chang KC, Leung CC, Grosset J, Yew WW. 2010. Treatment of tuberculosis and optimal dosing schedules. Thorax 66:997-1007.
9. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. 2006. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:1153-1158.
10. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. 2008. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am. J. Respir. Crit. Care Med. 177:1391-1396.
11. Chang KC, Leung CC, Yew WW, Tam CM. 2007. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur. Respir. J. 29:347-351.
12. Drusano GL. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36 (Suppl 1):S42-S50.
13. Duan JZ. 2009. Two commonly used methods for exposure-adverse events analysis: comparisons and evaluations. J. Clin. Pharmacol. 49:540-552.
14. Durand F, et al. 1995. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 21:929-932.
15. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. 1996. Hepatotoxicity ofantitubercular treatments. Rationale for monitoring liver status. Drug Saf. 15:394-405.
16. Escreet BC, Cowie RL. 1981. Short-course chemotherapy for pulmonary tuberculosis. A 100-day interrupted regimen. S. Afr. Med. J. 60:951-955.
17. Fernandez-Villar A, et al. 2004. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 8:1499-1505.
18. Girling DJ. 1978. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 59:13-32.
19. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antitu-berculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
20. Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1468-1481.
21. Hussain Z, Kar P, Husain SA. 2003. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J. Exp. Biol. 41:1226-1232.
22. Kleeberg HH, Swart DJ, Carey SM. 1983. The tolerability and efficacy of a 6-month antituberculosis regimen containing rifampicin, isoniazid and pyrazinamide. S. Afr. Med. J. 64:693-696.
23. Kuczmarski RJ, et al. 2000. CDC growth charts: United States. Adv. Data (314):1-27.
24. Kuczmarski RJ, et al. 2002. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. (246):111-190.
25. Lee AM, Mennone JZ, Jones RC, Paul WS. 2002. Risk factors for hepa-totoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int. J. Tuberc. Lung Dis. 6:995-1000.
26. Lee SW, et al. 2010. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 14:622-626.
27. Makhlouf HA, Helmy A, Fawzy E, El-Attar M, Rashed HA. 2008. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol. Int. 2:353-360.
28. Matthews JH. 1960. Pyrazinamide and isoniazid used in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 81:348-351.
29. McDermott W, et al. 1954. Pyrazinamide-isoniazid in tuberculosis. Am. Rev. Tuberc. 69:319-333.
30. McIlleron H, et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
31. McNeill L, Allen M, Estrada C, Cook P. 2003. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 123:102-106.
32. Mitchison DA, Davies GR. 2008. Assessment of the efficacy of new antituberculosis drugs. Open Infect. Dis. J. 2:59-76.
33. Mount FW, Wunderlich GS, Murray FJ, Ferebee SH. 1959. Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. Public Health Serv. Invest. 1(50):371-387.
34. Pasipanodya JG, Gumbo T. 2011. An oracle: antituberculosis pharma-cokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 55:24-34.
35. Pasipanodya JG, Gumbo T. 2010. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob. Agents Chemother. 54:2847-2854.
36. Peloquin CA, et al. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41: 2670-2679.
37. Phillips S, Horton GE. 1956. Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance. Am. Rev. Tuberc. 73:704-715.
38. Ramakrishnan CV, et al. 1968. Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients. Bull. World Health Organ. 39:775-779.
39. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
40. Santen G, Horrigan J, Danhof M, Della Pasqua O. 2009. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin. Pharmacol. Ther. 86:255-262.
41. Saukkonen JJ, et al. 2006. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 174:935-952.
42. Sharma SK, et al. 2010. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin. Infect. Dis. 50:833-839.
43. Singh J, et al. 1995. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad. Med. J. 71:359-362.
44. Steele MA, Des Prez RM. 1988. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845-850.
45. Tahaoglu K, et al. 2001. The management of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 5:65-69.
46. Teleman MD, Chee CB, Earnest A, Wang YT. 2002. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int. J. Tuberc. Lung Dis. 6:699-705.
47. Tost JR, et al. 2005. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int. J. Tuberc. Lung Dis. 9:534-540.
48. Tostmann A, et al. 2008. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 23:192-202.
49. United States Public Health Service. 1959. Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. United States Public Health Service Tuberculosis Therapy Trial. Am. Rev. Respir. Dis. 80:371-387.
50. Vasantha M, Gopi PG, Subramani R. 2009. Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS). Indian J. Tuberc. 56:5-9.
51. Wilkins JJ, et al. 2006. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62:727-735.
52. World Health Organization. 2010. WHO report: global tuberculosis control. World Health Organization, Geneva, Switzerland.
53. Zhang L, et al. 2006. Model-based drug development: the road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 33:369-393.